| Literature DB >> 35028278 |
Charit Taneja1, Pouneh K Fazeli1, Paul A Gardner2, Eric W Wang3, Carl H Snyderman3, Hussain Mahmud1.
Abstract
This report describes a case of pituitary apoplexy with rapidly evolving hemorrhage in a 74-year-old female with coronavirus disease 2019 (COVID-19) disease. The patient presented with severe headache and mild respiratory symptoms, with laboratories concerning for pituitary hypofunction. Brain imaging demonstrated a sellar mass concerning for a pituitary adenoma with ischemic apoplexy. She subsequently developed visual deficits within 24 hours of presentation, and repeat imaging demonstrated evolving hemorrhage and new mass effect on the optic chiasm. She was successfully managed with urgent endoscopic endonasal surgery despite her COVID-19 positive status by taking special intraoperative precautions to mitigate SARS-CoV2 transmission risk. Only a handful of cases of pituitary apoplexy have been reported in association with COVID-19 disease, and even fewer reports exist of endonasal procedures in such cases. We discuss the potential implication of COVID-19 in the occurrence of pituitary apoplexy, in addition to the safety and success of endonasal surgery in this population. The Author(s). This is an open access article published by Thieme under the terms of the Creative Commons Attribution-NonDerivative-NonCommercial License, permitting copying and reproduction so long as the original work is given appropriate credit. Contents may not be used for commercial purposes, or adapted, remixed, transformed or built upon. ( https://creativecommons.org/licenses/by-nc-nd/4.0/ ).Entities:
Keywords: COVID-19; endonasal surgery; pituitary apoplexy
Year: 2022 PMID: 35028278 PMCID: PMC8747894 DOI: 10.1055/s-0041-1742104
Source DB: PubMed Journal: J Neurol Surg Rep ISSN: 2193-6358
Fig. 1Coronal ( A ) and axial ( B ) MRI demonstrating a poorly enhancing pituitary macroadenoma with suprasellar extension. The lack of enhancement combined with patient symptoms is suggestive of ischemic apoplexy without overt hemorrhage. MRI, magnetic resonance imaging.
Hormone levels at presentation
| Test | Result | Reference range |
|---|---|---|
| ACTH | 9 | 9–46 pg/mL |
| Cortisol | 3 |
2–14 µg/dL
|
| Prolactin | 2.2 | 0.6–20 ng/mL |
| TSH | 1.543 | 0.3–5.0 µIU/mL |
| Free thyroxine | 0.61 | 0.89–1.78 ng/dL |
| Growth hormone | 0.77 | 0.01–8.00 ng/mL |
| LH | 0.5 |
9.0–52.3 mIU/mL
|
| FSH | 4.1 |
14.9–124.3 mIU/mL
|
| IGF-1 | 45 | 34–245 ng/mL |
Abbreviations: ACTH, adrenocorticotropic hormone; FSH, follicle-stimulating hormone; IGF-1, insulin-like growth factor 1; LH, luteinizing hormone; TSH, thyroid-stimulating hormone.
Sample obtained between 4 and 6 pm.
For postmenopausal females.
Fig. 2Coronal ( A ) and axial ( B ) MRIs obtained after worsening of patient symptoms demonstrate interval (<24 hours) hemorrhage into the tumor ( arrow ). MRI, magnetic resonance imaging.